Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enzastaurin + erlotinib
- Development stage
- Phase 2
- Lead developer
- Denovo Biopharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of enzastaurin, an oral serine/threonine kinase inhibitor targeting protein kinase C (PKC) and phosphatidylinositol-3-kinase (PI3K) pathways, and erlotinib, an epidermal growth factor receptor (EGFR) inhibitor. This combination was developed to potentially overcome EGFR resistance in cancer treatment based on preclinical models.
02
Targets
EGFR (Epidermal growth factor receptor)PRKCB (Protein kinase C beta)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)PKC (Protein kinase C family)
Beyond the preview
Go deeper on enzastaurin + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enzastaurin + erlotinib.